Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
27.96
Nov 19 • 3:59 PM ET Dollar change+0.41 Percentage change(1.49%)
Aftermarket Close
27.00
Aftermarket • 7:57 PM ET Dollar change-0.96 Percentage change(-3.43%)
Nov 19, 4:35 PMCelldex’s Phase 2 barzolvolimab study in atopic dermatitis missed its primary and key secondary endpoints, prompting the company to discontinue development in the indication.
Index
RUT
Market Cap
2.20B
Enterprise Value
1.56B
Income
-309.06M
Sales
0.16M
Book/sh
8.27
Cash/sh
8.21
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
198
IPO
May 15, 1986
P/E
-
Forward P/E
-
PEG
-
P/S
13725.75
P/B
3.38
P/C
3.41
P/FCF
-
EV/EBITDA
-
EV/Sales
9757.31
Quick Ratio
10.97
Current Ratio
10.97
Debt/Eq
0.02
LT Debt/Eq
0.01
Option/Short
Yes / Yes
EPS (ttm)
-4.31
EPS next Y
-4.00
EPS next Q
-1.00
EPS this Y
-4.60%
EPS next Y
1.91%
EPS next 5Y
5.26%
EPS past 3/5Y
-17.59% -14.07%
Sales past 3/5Y
-13.13% -26.93%
EPS Y/Y TTM
-27.48%
Sales Y/Y TTM
-93.92%
EPS Q/Q
4.69%
Sales Q/Q
-
Insider Own
3.32%
Insider Trans
0.00%
Inst Own
111.33%
Inst Trans
24.24%
ROA
-45.12%
ROE
-49.54%
ROIC
-46.98%
Gross Margin
-2263.29%
Oper. Margin
-211684.81%
Profit Margin
-195608.86%
SMA20
-4.72%
SMA50
-10.12%
SMA200
-15.04%
Trades
Shs Outstand
78.53M
Shs Float
75.94M
52W High
45.14 -38.06%
52W Low
22.33 25.21%
Volatility
4.41% 4.77%
ATR (14)
1.44
RSI (14)
40.94
Beta
1.04
Rel Volume
0.57
Avg Volume
1.33M
Volume
751,772
Perf Week
-2.00%
Perf Month
-4.80%
Perf Quarter
-30.76%
Perf Half Y
-8.57%
Perf YTD
2.95%
Perf Year
12.20%
Perf 3Y
-3.88%
Perf 5Y
-34.95%
Perf 10Y
-57.92%
Prev Close
27.55
Price
27.96
Change %
1.49%
Consensus
Strong Buy
Avg. Price Target
$63.79
Implied Upside
+128.1%
Analysts16incl. previous ratings
Rating Distribution14 Buy · 2 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Sep 22, 2026Reiterated
HH.C. Wainwright
Buy$42 → $64+128.9%
Apr 20, 2026Upgrade
BCS logoBBarclays
Underweight → Overweight$45+60.9%
Mar 23, 2026Upgrade
WWolfe Research
Peer Perform → Outperform$44+57.4%
Oct 21, 2025Initiated
MFG logoMMizuho
Outperform$48+71.7%
Oct 13, 2025Initiated
BCS logoBBarclays
Underweight$25-10.6%
Apr 28, 2025Initiated
CCanaccord Genuity
Buy$64+128.9%
Mar 20, 2025Initiated
MS logoMMorgan Stanley
Overweight$46+64.5%
Feb 13, 2025Initiated
UBS logoUUBS
Buy$44+57.4%
Oct 07, 2024Initiated
C logoCCitigroup
Buy$70+150.4%
Sep 30, 2024Initiated
GS logoGGoldman
Neutral$45+60.9%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Martin Samuel BatesSVP AND CFOJan 02 '26Option Exercise10.384,81750,00032,942Jan 06 04:23 PM
PEPIN RONALDSR. VP & CBODec 15 '25Option Exercise5.4719,333105,71420,097Dec 17 04:06 PM
Jimenez Freddy A.SVP & GENERAL COUNSELDec 04 '25Sale29.094,166121,21030,796Dec 08 04:20 PM
FREDDY A JIMENEZOfficerDec 04 '25Proposed Sale29.104,166121,210Dec 04 04:04 PM
Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.
FounderMr. Anthony S. Marucci M.B.A.
FounderDr. Tibor Keler Ph.D.
Senior VPMr. Sam Martin CPA
Chief Product Development Officer & Senior VPMs. Elizabeth Crowley
Senior Vice President of Regulatory AffairsDr. Margo Heath-Chiozzi M.D.